Biotek-snakken — September 2021
-
Teknisk status for aktierne i C25: https://www.proinvestor.com/index.php?p=debat_1&postid=97148
-
San Antonio Breast Cancer Symposium® | SABCS 2026
The San Antonio Breast Cancer Symposium® (SABCS) is the world’s largest breast cancer research meeting, where leading scientists and clinicians share the latest breakthroughs advancing breast cancer research and patient care. Join the global breast cancer community in San Antonio, December 8–11, 2026.
San Antonio Breast Cancer Symposium - The San Antonio Breast Cancer Symposium® is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers. (www.sabcs.org)
-
Entasis: markedet for etx0462 ser ud til at være pænt stort, ifølge CDC var der i 2019 400K US tilfælde i ESKAPE pathogen gruppen. Det må i det mindste give lidt plus på BO prisen - tvivler på, at vi når at se resultater i klinikken før det siger haps
-
Tror vi har snakket om det før, men ville Novartis ikke være oplagt partner til Zani og ZW49? Nu når de har rettighederne til tislelizumab i US, EU og Japan og endnu ikke er i HER2 gamet
-
Breakthrough AstraZeneca Breast Cancer Drug Massively Reduces Disease and Fatalities in Trialhttps://www.proinvestor.com/investornyt/707066/breakthrough-astrazeneca-breast-cancer-drug-massively-reduces-disease-and-fatalities-in-trial
-
Nyhed fra igår:
XBRANE: BIOGEN FÅTT USA-GODKÄNT FÖR BIOSIMILAR TILL LUCENTIS -
-
Cantargia AB: Cantargia: FDA tilldelar särläkemedelsstatus (Orphan Drug Designation) till nadunolimab för behandling av bukspottkörtelcancer
Cantargia AB meddelade idag att den amerikanska läkemedelsmyndigheten, Food and Drug Administration (FDA), har beviljat särläkemedelsstatus i USA till nadunolimab (CAN04) för behandling av bukspottkörtelcancer. Detta ger möjlighet att utnyttja flertal incitament vid den fortsatta kliniska utvecklingen av nadunolimab i bukspottkörtelcancer -
Ja, noget af en rutschebanetur vi har været på
fra 14 til 70 og tilbage til 20. Og nu i 25…kunne være rart med en lidt opadgående tendens igen, istedetfor den sivendende tendens vi har set i lang tid.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind